Influence of the N-terminal region on the oligomerisation between human and Xenopus laevis p53

Journal of Molecular Biology

Volumn 288, Issue 5, 1999, Pages 883-890

  Chène, Patrick ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Oligomerisation; p53; Tetramerisation

Indexed keywords

PROTEIN P53;

AMINO TERMINAL SEQUENCE; ARTICLE; DELETION MUTANT; HUMAN; MOUSE; NONHUMAN; OLIGOMERIZATION; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN STRUCTURE; XENOPUS LAEVIS;

MURINAE; XENOPUS LAEVIS;

EID: 0033591241     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1006/jmbi.1999.2734     Document Type: Article

References (19)

1. Caelles C., Helmberg A., Karin M. p53-dependent apoptosis in the absence of transcriptional activation of p53-target genes. Nature. 370:1994;220-223.
2. Chène P., Mittl P., Grütter M. In vitro structure-function analysis of the β-strand 326-333 of human p53. J. Mol. Biol. 273:1997;873-881.
3. Clore G. M., Omichinski J. G., Sakaguchi K., Zambrano N., Sakamoto H., Appella E., Gronenborn A. M. High-resolution structure of the oligomerisation domain of p53 by multidimensional NMR. Science. 265:1994;386-391.
4. El-Deiry W. S., Tokino T., Velculescu V. E., Levy D. B., Parsons R., Trent J. M., Lin D., Mercer W. E., Kinzler K. W., Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell. 75:1993;817-825.
5. Halazonetis T. D., Kandil A. N. Conformational shifts propagate from the oligomerisation domain of p53 to its tetrameric DNA binding domain and restore DNA binding to select p53 mutants. EMBO J. 12:1993;5057-5064.
6. Harris C. C. Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. J. Int. Natl Cancer Inst. 88:1996;1442-1455.
7. Haupt Y., Rowan S., Shaulian E., Vousden K. H., Oren M. Induction of apoptosis in HeLa cells by trans-activation-deficient p53. Genes Dev. 9:1995;2170-2183.
8. Hoever M., Clement J. H., Wedich D., Montenarh M., Knochel W. Overexpression of wild-type p53 interferes with normal development in Xenopus laevis embryos. Oncogene. 9:1994;109-120.
9. Hupp T. R., Meek D. W., Midgley C. A., Lane D. P. Regulation of the specific DNA binding function of p53. Cell. 71:1992;875-886.
10. Jayaraman L., Freulich E., Prives C. Functional dissection of p53 tumor suppressor protein. Methods Enzymol. 283:1997;245-256.
11. Jeffrey P. D., Gorina S., Pavletich N. P. Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 angstroms. Science. 267:1995;1498-1502.
12. Ko L. J., Prives C. p53: puzzle and paradigm. Genes Dev. 10:1996;1054-1072.
13. Lee W. L., Harvey T. S., Yin Y., Yau P., Litchfield D., Arrowsmith C. H. Solution structure of the tetrameric minimum transforming domain of p53. Nature Struct. Biol. 1:1994;877-890.
14. Milner J., Medcalf E. A. Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation. Cell. 65:1991;765-774.
15. Soussi T., May P. Structural aspects of the p53 protein in relation to gene evolution: a second look. J. Mol. Biol. 260:1996;623-637.
16. Soussi T., Caron de Fromentel C., May P. Structural aspects of the p53 protein in relation to gene evolution. Oncogene. 5:1990;945-952.
17. Wagner A. J., Kokontis J. M., Hay N. Myc-mediated apoptosis requires wild-type p53 in a manner independent of cell cycle arrest and the ability of p53 to induce p21waf1/cip1. Genes Dev. 8:1994;2817-2830.
18. Wang Y., Farmer G., Soussi T., Prives C. Xenopous laevis p53 protein: sequence-specific DNA binding, transcriptional regulation and oligomerisation are evolutionarily conserved. Oncogene. 10:1995;779-784.
19. Waterman J. L. F., Shenk J. L., Halozonetis T. D. The dihedral symmetry of the p53 tetramerization domain mandates a conformational switch upon DNA binding. EMBO J. 14:1995;512-519.